Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
10.53
+0.05 (0.48%)
Aug 22, 2025, 4:00 PM - Market closed
Arcus Biosciences Revenue
Arcus Biosciences had revenue of $160.00M in the quarter ending June 30, 2025, with 310.26% growth. This brings the company's revenue in the last twelve months to $262.00M, up 6.07% year-over-year. In the year 2024, Arcus Biosciences had annual revenue of $258.00M with 120.51% growth.
Revenue (ttm)
$262.00M
Revenue Growth
+6.07%
P/S Ratio
3.90
Revenue / Employee
$417,863
Employees
627
Market Cap
1.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 258.00M | 141.00M | 120.51% |
Dec 31, 2023 | 117.00M | 5.00M | 4.46% |
Dec 31, 2022 | 112.00M | -271.00M | -70.76% |
Dec 31, 2021 | 383.00M | 305.00M | 391.03% |
Dec 31, 2020 | 78.00M | 63.00M | 420.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RCUS News
- 2 days ago - Arcus Biosciences to Participate in Three Upcoming Investor Conferences - Business Wire
- 8 days ago - Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus - Benzinga
- 12 days ago - Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months - Seeking Alpha
- 16 days ago - Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update - Business Wire
- 4 weeks ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 weeks ago - Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer - Business Wire
- 2 months ago - Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response - Business Wire
- 3 months ago - Arcus Biosciences, Inc. (RCUS) Q1 2025 Earnings Call Transcript - Seeking Alpha